Briefing
3O Association of ctDNA clearance with disease-free survival, safety, and quality of life from ctDNA-directed therapy: Findings from the ALTAIR study
ctDNA clearance at treatment completion was 17.2% with FTD/TPI vs 12.4% with placebo (P=0.367), a non-significant difference. Grade >=3 neutropenia occurred in 56.6% on FTD/TPI; 37.7% required dose reduction. Global health status declined at week 8 on FTD/TPI (P=0.028) but arms did not differ from week 24 onward. DFS results match the ASCO GI primary report (HR 0.79, P=0.107).
- Design: oral
- n: 243
- Assay: Signatera (Natera)